52 North Health

Founded in 2018 by Umaima Ahmad, Saif Ahmad, and Mireia Crispin Ortuzar, Cambridge-based 52 North Health develops AI-driven point-of-care medical devices for oncology patients. The company's flagship product, Neutrocheck, is a portable at-home finger-prick blood test that quickly assesses the risk of neutropenic sepsis in active chemotherapy patients. By enabling at-risk individuals to safely triage their health status outside of clinical settings, this breakthrough technology aims to improve urgent care pathways and significantly reduce unnecessary emergency room visits. Operating with an estimated headcount of under twenty employees, the medical technology firm has secured approximately ten million dollars in total venture funding to date. This capital includes a recent six million dollar funding round alongside a substantial government grant, featuring backing from notable institutional investors such as KHP Ventures, Cedars-Sinai, Macmillan Cancer Support, and Cambridge Enterprise.